Prime-boost immunization with DNA, recombinant fowlpox virus and VLPSHIV elicit both neutralizing antibodies and IFNγ-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells

Vaccine

Volumn 25, Issue 11, 2007, Pages 2128-2138

  Radaelli, Antonia ^a   Bonduelle, Olivia ^b   Beggio, Paola ^a   Mahe, Brice ^b   Pozzi, Eleana ^a   Elli, Veronica ^a   Paganini, Manuela ^a   Zanotto, Carlo ^a   Morghen, Carlo De Giuli ^a   Combadière, Béhazine ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

B77 tumour cell challenge; Fowlpox virus; Prime boost; Recombinant vaccines; VLPs

Indexed keywords

DNA VACCINE; ENVELOPE PROTEIN; FOWLPOX VIRUS VECTOR; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CANCER CONTROL; CONTROLLED STUDY; DNA VECTOR; DRUG EFFICACY; ENVELOPE GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOWLPOX VIRUS; GENE EXPRESSION; GENE FREQUENCY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOFLUORESCENCE; IMMUNOGENICITY; INTERFERON PRODUCTION; MACACA; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURAL GENE; T LYMPHOCYTE; TRANSGENE; TUMOR CELL; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS RECOMBINANT;

AIDS VACCINES; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; DNA, RECOMBINANT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOWLPOX VIRUS; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV-1; IMMUNIZATION, SECONDARY; INTERFERON TYPE II; MICE; MICROSCOPY, FLUORESCENCE; NEOPLASMS; NEUTRALIZATION TESTS; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VIROSOMES;

EID: 33846894323     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.009     Document Type: Article

References (60)

1. Dittmer U., Brooks D.M., and Hasenkrug K.J. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nat Med 5 (1999) 1891-1893
2. Heeney J.L., Holterman L., ten Haaft P., Dubbes R., Koomstra W., Teeuwsen V.J.P., et al. Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge. AIDS Res Hum Retroviruses 10 (1994) S117-S121
3. De Giuli Morghen C., Radaelli A., Zanotto C., Marconi P., and Manservigi R. Virus vectors for immunoprophylaxis. AIDS Rev 2 (2000) 127-135
4. Abimiku A.G., Franchini G., Tartaglia J., Aldrich K., Myagkikh M., Markham P.D., et al. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med 1 (1995) 321-329
5. Baxby D., and Paoletti E. Potential use of nonreplicating vectors as recombinant vaccines. Vaccine 10 (1992) 8-9
6. Somogyiwbo P., Frazier J., and Skinner M.A. Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology 197 (1993) 439-444
7. Franchini G., Gurunathan S., Baglyos L., Plotkin S., and Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 3 (2004) S75-S88
8. Nacsa J., Radaelli A., Edghill-Smith Y., Venzon D., Tsai W.P., De Giuli Morghen C., et al. Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques. Vaccine 22 (2004) 597-606
9. Skinner M.A., Laidlaw S.M., Eldaghayes I., Kaiser P., and Cottingham M.G. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev Vaccines 4 (2005) 63-76
10. De Rose R., Chea S., Dale C.J., Reece J., Fernandez C.S., Wilson K.M., et al. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine 23 (2005) 1949-1956
11. Taylor J., Weinberg R., Languet B., Desmettre P., and Paoletti E. Recombinant fowlpox virus inducing protective immunity in nonavian species. Vaccine 6 (1988) 497-503
12. Jenkins S., Gritz L., Fedor C.H., O'Neill E., Cohen L.K., and Panicali D.L. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. AIDS Res Hum Retroviruses 7 (1991) 991-997
13. Robinson H.L., Montefiori D.C., Johnson R.P., Manson K.H., Kalish M.L., Lifson J.D., et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5 (1999) 526-534
14. Dale C.J., De Rose R., Stratov I., Chea S., Montefiori D.C., Thomson S., et al. Efficacy of DNA and fowlpox virus priming/boosting vaccines for Simian/Human Immunodeficiency virus. J Virol 78 (2004) 13819-13828
15. Kent S.J., Zhao A., Best S.J., Chandler J.D., Boyle D.B., and Ramshaw I.A. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 72 (1998) 10180-10188
16. Vazquez-Blomquist D., Green P., Laidlaw S.M., Skinner M.A., Borrow P., and Duarte C.A. Induction of a strong HIV-specific CD8+ T-cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide. Viral Immunol 15 (2002) 337-356
17. Coupar B.E.H., Purcell D.F.J., Thomson S.A., Ramshaw I.A., Kent S.J., and Boyle D.B. Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine 24 (2006) 1378-1388
18. Hodge J.W., Grosenbach D.W., Aarts W.M., Poole D.J., and Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 9 (2003) 1837-1849
19. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Topalian S.L., Sherry R.M., et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 9 (2003) 2973-2980
20. Triozzi P.L., Aldrich W., Allen K.O., Lima J., Shaw D.R., and Strong T.V. Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma. Int J Cancer 113 (2004) 406-414
21. Vuola J.M., Keating S., Webster D.P., Berthoud T., Dunachie S., and Gilbert S.C. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 174 (2005) 449-455
22. Clements-Mann M.L., Weinhold K., Matthews T.J., Graham B.S., Gorse G.J., Keefer M.C., et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1(MN) gp120, HIV-1(SF2) recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 177 (1998) 1230-1246
23. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
24. Tartaglia J., Excler J.L., El Habib R., Limbach K., Meigneier B., Plotkin S., et al. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses 14 (1998) S291-S298
25. Voss G., and Letvin N.L. Definition of human immunodeficiency virus type 1 gp120 and gp41 cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I alleles in simian-human immunodeficiency virus-infected rhesus monkeys. J Virol 70 (1996) 7335-7340
26. Larsson M., Jin X., Ramratnam B., Ogg G.S., Engelmayer J., Demoitie M.A., et al. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 13 (1999) 767-777
27. Propato A., Schiaffella E., Vicenzi E., Francavilla V., Baloni L., Paroli M., et al. Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Human Immunol 62 (2001) 561-576
28. Barnett S.W., Klinger J.M., Doe B., Walker C.M., Hansen L., Duliege A.M., et al. Prime-boost immunization strategies against HIV. AIDS Res Hum Retroviruses 14 (1998) S299-S309
29. Salmon-Ceron D., Excler J.L., Finkielsztejn L., Autran B., Gluckman J.C., Sicard D., et al. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI. AIDS Res Hum Retroviruses 15 (1999) 633-645
30. Vinner L., Nielsen H.V., Bryder K., Corbet S., Nielsen C., and Fomsgaard A. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene. Vaccine 17 (1999) 2166-2175
31. Desrosiers R.C. Non human primate models for AIDS vaccines. AIDS 9 (1995) S137-S141
32. Haffar O., Garrigues J., Travis B., Moran P., Zarling J., and Hu S.L. Human immunodeficiency virus-like particles assemble in a recombinant vaccinia virus expression system. J Virol 64 (1990) 2653-2659
33. Haglund K., Forman J., Kraeusslich H.G., and Rose J.K. Expression of human immunodeficiency virus type 1 gag protein precursor and envelope proteins from a Vesicular Stomatitis Virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 268 (2000) 112-121
34. Smith A.J., Cho M.I., Hammarskjoeld M.L., and Rekosh D. Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into virus like particles. J Virol 64 (1990) 2743-2750
35. gag virus-like particles by an Epstein-Barr Virus gp220/350-derived transmembrane domain. Virology 235 (1997) 10-25
36. Deml L., Schirmbeck R., Reimann J., Wolf H., and Wagner R. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology 235 (1997) 26-39
37. Bonauguro L., Racioppi L., Tornesello M.L., Arra C., Visciano M.L., Biryahwaho B., et al. Induction of neutralizing antibodies and cytotoxic T-lynphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from HIV-1 isolate of clade A. Antiviral Res 54 (2002) 189-201
38. Haynes J.R., Cao S.X., Rovinski B., Sia C., James O., Dekaban G.A., et al. Production of immonogenic HIV-1 virus-like particles in stably engineered monkey cell lines. AIDS Res Hum Retroviruses 7 (1991) 17-27
39. Zanotto C., Paganini M., Elli V., Basavecchia V., Neri M., De Giuli Morghen C., et al. Molecular and biological characterization of simian-human immunodeficiency virus-like particles produced by recombinant fowlpox viruses. Vaccine 23 (2005) 4745-4753
40. Jarvis D.L., and Finn E.E. Biochemical analysis of the N-glycosylation pathway in baculovirus-infected lepidopteran insect cells. Virology 212 (1995) 500-511
41. Hel Z., Tsai W.P., Thornton A., Nacsa J., Giuliani L., Tryniszewska E., et al. Potentiation of Simian Immunodeficiency Virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J Immunol 167 (2001) 7180-7191
42. Radaelli A., Nacsa J., Tsai W.P., Edghill-Smith Y., Zanotto C., Elli V., et al. Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251. Virology 312 (2003) 181-195
43. Hanke T., Samuel R.V., Blanchard T.J., Neumann V.C., Allen T.M., Boyson J.E., et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus ankara boost vaccination regimen. J Virol 73 (1999) 7524-7532
44. Hel Z., Nacsa J., Tryniszewska E., Tsai W.P., Parks R.W., Montefiori D.C., et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4(+) and CD8(+) T cell responses. J Immunol 169 (2002) 4778-4784
45. Kent S.J., Zhao A., Dale C.J., Land S., Boyle D.B., and Ramshaw I.A. A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques. Vaccine 18 (2000) 2250-2256
46. Ramsay A.J., Kent S.J., Strugnell R.A., Suhrbier A., Thomson S.A., and Ramshaw I.A. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol Rev 171 (1999) 27-44
47. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
48. Cox W.J., Tartaglia J., and Paoletti E. Induction of cytotoxic T lymphocytes by recombinant canarypox and attenuated vaccinia viruses expressing the HIV-1 envelope glycoprotein. Virology 67 (1993) 845-850
49. Haddrick M., Han-liu Z., Lau A., Heaphy S., and Cann A.J. Production of non-infectious human immunodeficiency virus-like particles which package specifically viral RNA. J Virol Meth 61 (1996) 89-93
50. Radaelli A., Zanotto C., Perletti G., Elli V., Vicenzi E., Poli G., et al. Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmid and virus-like particles in prime-boost vaccination protocols against SHIV. Vaccine 21 (2003) 2052-2064
51. Kang C.Y., Luo L., Wainberg M.A., and Li Y. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Biol Chem 380 (1999) 353-364
52. Haffar O.K., Smithgall M.D., Moran P.A., Travis B.M., Zarling J.M., and Hu S.L. HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles. Virology 183 (1991) 487-495
53. Paliard X., Liu Y., Wagner R., Wolf H., Baenziger J., and Walker C.M. priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T-cells after administration of a virus-like particles vaccine in rhesus macaques. AIDS Res Hum Retroviruses 16 (2000) 273-282
54. Wagner R., Teeuwsen V.J.P., Deml L., Notka F., Haaksma A.G.M., Jhagjhoorsingh S.S., et al. Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection. Virology 245 (1998) 65-74
55. Harrington L.E., Most R.R., Whitton J.L., and Ahmed R. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 76 (2002) 3329-3337
56. Gurunathan S., Wu C.Y., Freidag B.L., and Seder R.A. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 12 (2000) 442-447
57. Ramshaw I.A., and Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 21 (2000) 163-165
58. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4 (1998) 397-402
59. Sedegah M., Jones T.R., Kaur M., Hedstrom R., Hobart P., Tine J.A., et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 95 (1998) 7648-7653 95, 7648-7653
60. Lu S., Arthos J., Montefiori D.C., Yasutomi Y., Manson K., Mustafa F., et al. Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 70 (1996) 3978-3991